Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Dr. Mingyao Liu's latest study, co-led by Toronto General Hospital Research Institute (TGHRI) Senior Scientist
Dr. Shaf Keshavjee, details how developing profiles of metabolic changes in donor lungs might be used to predict whether the organs are suitable for transplantation.
"Our study sheds light on a new way to assess donor lungs for transplantation," says Dr. Liu, TGHRI Senior Scientist.
Currently, donor lungs are assessed with imprecise approaches. As a result, many are classified as "marginal" lungs that are unsuitable for transplantation because of the risk of developing a condition known as primary graft dysfunction (PGD).
While the most severe form of PGD is associated with one in two deaths after transplantation, there is currently no way to predict which lungs will progress to PGD.
In pursuit of a way to predict which lungs are at risk of PGD, the research team of Drs. Liu and Keshavjee examined donor lungs undergoing a procedure that they developed known as ex vivo lung perfusion (EVLP).
EVLP involves pumping a special fluid through cold preserved donor lungs to rewarm the organ outside of the body and to be ventilated with oxygen. This enables the lungs to be objectively assessed for lung function and transplant suitability — resulting in recovery and successful transplantation of almost 90 per cent of lungs that would otherwise be classified as marginal.
The researchers hypothesized that rewarming the lungs during EVLP would cause detectable changes in metabolism that could help predict the risk of PGD. To examine these changes, the team collected the fluid being pumped through the organ during EVLP, and used a sophisticated technique called mass spectrometry to analyze approximately 275 chemical products present in the fluid.
After applying advanced mathematical approaches, they developed metabolic profiles to create a predictive model that could determine which lungs would progress to severe PGD.
"We're now one step closer to being able to personalize the surgery — helping each recipient find the right pair of donor lungs to improve the outcomes of the transplantation," Dr. Keshavjee explains.
This work was supported by the Canadian Institutes of Health Research and the Toronto General & Western Hospital Foundation. MY Liu is James and Mary Davie Chair in Lung Injury, Repair and Regeneration, and M Cypel is a Tier 2 Canada Research Chair in Lung Transplantation.